AA
FSTX

AlphaCentric Advisors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

AlphaCentric Advisors’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-165,000
Closed -$845K – 222
2022
Q3 		$845K Buy
+165,000
New +$1.04M 0.87% 37

Other funds holding FSTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AlphaCentric Advisors's FSTX Position: Q4 2022 in Review

AlphaCentric Advisors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2022, closing a stake of 165,000 shares — an estimated $845K sold.

AlphaCentric Advisors first reported a position in FSTX in Q3 2022 and held it in 1 quarter. The position peaked at $845K in Q3 2022. 59 funds tracked by Wall St. Rank hold FSTX as of Q4 2022.

  • AlphaCentric Advisors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • AlphaCentric Advisors sold 165,000 F-star Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $845K.
  • AlphaCentric Advisors first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • AlphaCentric Advisors's F-star Therapeutics, Inc. Common Stock position peaked at $845K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2022.

Based on AlphaCentric Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.